Strategies for augmentation of SSRI treatment: A survey of an academic psychopharmacology practice

Harvard Review of Psychiatry

Volumn 6, Issue 6, 1999, Pages 322-326

  Mischoulon, David ^a   Fava, Maurizio ^b   Rosenbaum, Jerrold F ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; DEXAMPHETAMINE; ESTROGEN; INOSITOL; KETOCONAZOLE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; OPIATE; PEMOLINE; PINDOLOL; PRAMIPEXOLE; PRASTERONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; YOHIMBAN DERIVATIVE;

DEPRESSION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HYPERICUM PERFORATUM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL FUNCTION; TREATMENT PLANNING;

EID: 0033000239     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229909017210     Document Type: Review

References (28)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
2. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;24:281-90.
3. Rosenbaum JF, Fava M, Nierenberg AA, Sachs GS. Treatment-resistant mood disorders. In: Gabbard GO, ed. Treatments of psychiatric disorders, vol. 1. 2nd ed. Washington, DC: American Psychiatric Press, 1995:1276-328.
4. Shergill SS, Katona CL. Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. J Affect Disord 1997;43:19-25.
5. Nierenberg AA. Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. J Clin Psychiatry 1991;52:383-5.
6. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv 1997;48:835-7.
7. Dinan TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 1993;88:300-1.
8. Schweitzer I, Tuckwell V, Johnson G. A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician. Aust N Z J Psychiatry 1997;31:340-52.
9. Hänsgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the Hypericum extract LI 160. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S15-8.
10. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry 1993;54(9, suppl):42-9.
11. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-93.
12. Hjorth S. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol 1996;303:183-6.
13. Tome MB, Cloninger CR, Watson JP, Isaac MT. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. J Affect Disord 1997;44:101-9.
14. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-9.
15. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-4.
16. Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol 1996;11:55-7.
17. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996;128:421-5.
18. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
19. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997;87(4, suppl):534-7, 540.
20. Sprenger D. Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence [Letter]. J Clin Psychopharmacol 1997;17:425-6.
21. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-21.
22. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull 1996;32:175-80.
23. Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-6.
24. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996;32:677-82.
25. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58: 119-22.
26. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-6.
27. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
28. Gerner RH, Kaufman KR, Rosen R. Seizures associated with bupropion and SSRI co-therapy [Abstract]. Biol Psychiatry 1998;43(8, suppl):99S.